CTFA/CHPA Urge More Flexibility in Gingivitis Draft Guidance
This article was originally published in The Tan Sheet
Executive Summary
FDA's draft guidance for antigingivitis drug development and evaluation should encourage the creation of new indices that provide "meaningful and clinically relevant measures" of gingivitis, according to industry trade groups
You may also be interested in...
Gingivitis comments
FDA's draft guidance on gingivitis products "attempt[s] to establish certain standards for the design and evaluation of studies that go further than scientifically and clinically desirable and appropriate," Church & Dwight states in Oct. 27 comments to the agency. The guidance was released in June by FDA to aid sponsors with developing Rx and OTC products to treat gingivitis. "When standards are set unnecessarily and inappropriately high, useful products whose benefits exceed their risk cannot come to market," C&D adds. In a separate submission, J&J suggests specifying blinded trial requirements and revising the phrasing of inclusion/exclusion criteria. The Consumer Healthcare Products Association also submitted comments in October (1"The Tan Sheet" Nov. 7, 2005, p. 10)...
CTFA/CHPA Urge Expanded Oral Health Care Indications
FDA should broaden labeling guidance for the indications of OTC antigingivitis/antiplaque drug products under the "uses" heading to allow multiple descriptions of drug effects, the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry & Fragrance Association recommends
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC